Materials and methods for gene therapy

Details Materials and methods for gene therapy Materials and methods for gene therapy

1999-04-23

2002-10-08

Priebe, Scott D. (Department: 1636)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093210, C424S093600, C514S04400A, C435S320100, C435S325000, C435S069100, C435S455000, C536S023100, C536S023500

Reexamination Certificate

active

06461606

ABSTRACT:

BACKGROUND OF THE INVENTION
Alpha-1-antitrypsin (AAT) deficiency is the second most common monogenic lung disease in man, accounting for approximately 3% of all early deaths due to obstructive pulmonary disease. AAT protein is normally produced in the liver, secreted into the serum and circulated to the lung where it protects the fine supporting network of elastin fibers from degradation by neutrophil elastase. Current therapy for AAT deficiency includes avoidance of cigarette smoke exposure and weekly intravenous infusions of recombinant human AAT (hAAT) protein. Attempts to devise gene therapy strategies to replace AAT either in the lung itself or within any of a number of other tissues which are capable of AAT secretion have been limited by the short duration of expression from some vectors and by the relatively high circulating levels of AAT which is required for therapeutic effect. Methods of gene therapy have been described in U.S. Pat. No. 5,399,346.
It has recently been demonstrated that adeno-associated virus (AAV) vectors are capable of stable in vivo expression and may be less immunogenic than other viral vectors (Flotte et al., 1996; Xiao et al., 1996; Kessler et al., 1996; Jooss et al., 1998). AAV is a non-pathogenic human parvovirus whose life cycle naturally includes a mechanism for long-term latency. In the case of wild-type AAV (wtAAV), this persistence is due to site-specific integration into a site on human chromosome 19 (the AAVSI site) in the majority of cells (Kotin et al., 1990), whereas with recombinant AAV (rAAV) vectors, persistence appears to be due to a combination of episomal persistence and integration into non-chromosome 19 locations (Afione et al., 1996; Kearns et al., 1996). Recombinant AAV latency also differs from that of wtAAV in that wtAAV is rapidly converted to double-stranded DNA in the absence of helper virus (e.g., adenovirus) infection, while with rAAV leading strand synthesis is delayed in the absence of helper virus (Fisher et al., 1996; Ferrari et al., 1996). U.S. Pat. No. 5,658,785 describes adeno-associated virus vectors and methods for gene transfer to cells.
Kessler et al. (1996) demonstrated that murine skeletal myofibers transduced by an rAAV vector were capable of sustained secretion of biologically active human erythropoietin (hEpo), apparently without eliciting a significant immune response against the secreted hEpo. See also U.S. Pat. No. 5,858,351 issued to Podsakoff et al. Likewise, Murphy et al. (1997) have observed the expression and secretion of sustained levels of leptin in ob/ob mice after AAV muscle transduction. Brantly et al. (U.S. Pat. No. 5,439,824) disclose methods for increasing expression of AAT using vectors comprising intron II of the human AAT gene. However, the level of leptin expression observed was only in the range of 2 to 5 ng/ml. Therapy for AAT deficiency requires serum levels of at least about 800 &mgr;g/ml. Thus, there remains a need in the art for a means of providing therapeutically beneficial levels of a protein to a person in need of such treatment.
BRIEF SUMMARY OF THE INVENTION
The subject invention concerns materials and methods for gene therapy. One aspect of the invention pertains to vectors which can be used to provide genetic therapy in animals or humans having a genetic disorder where relatively high levels of expression of a protein is required to treat the disorder. The vectors of the invention are based on adeno-associated virus (AAV). The vectors are designed to provide high levels of expression of heterologous DNA contained in the vector. In one embodiment, the vectors comprise AAV inverted terminal repeat sequences and constitutive or regulatable promoters for driving high levels of gene expression. The subject invention also pertains to methods for treating animals or humans in need of gene therapy, e.g., to correct a genetic deficiency disorder.


REFERENCES:
patent: 4797368 (1989-01-01), Carter et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5439824 (1995-08-01), Brantly et al.
patent: 5587308 (1996-12-01), Carter et al.
patent: 5658776 (1997-08-01), Flotte et al.
patent: 5658785 (1997-08-01), Johnson
patent: 5846528 (1998-12-01), Podsakoff et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 5866696 (1999-02-01), Carter et al.
Anderson WF, Nature 392:25-30, 1998.*
Verma et al Nature 389:239-242, 1997.*
Kay et al, PNAS 94:12744-12746, 1997.*
Koeberl et al PNAS 94:1426-1431, 1997.*
Kessler et al PNAS 93(24):14082-7, 1996.*
Doll et al. Gene Ther. 3(5):437-447, 1996.*
Bodine et al Blood 82(7):1975-80, 1993.*
Rosenfeld et al Science 252(5004):374, 1991.*
Afione et al., “In vivo model of adeno-associated virus vector persistence and rescue,”Journal of Virology, 70:3235-3241, 1996.
Brantly et al., “Use of a highly purified alpha 1-antityrpsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes,”Chest100:703-708, 1991.
Fisher et al., “Transduction with recombinant adeno-associated virus for gene therapy is limited by leading strand synthesis,”J. Virol. 70:520-532, 1996.
Flotte et al., “Gene expression from adeno-associated virus vectors in airway epithelial cells,”Am. J. Respir. Cell Mol. Biol. 7:349-356, 1992.
Flotte et al., “Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter,”J. Biol. Chem. 268:3781-3790, 1993.
Flotte et al., “Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector,”Proc. Natl, Acad. Sci. USA, 90(22):10613-10617, 1993.
Flotte et al., “An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction,”Gene Ther. 2:29-37, 1995.
Jooss et al., “Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers,”J. Virol. 72:4212-4223, 1998.
Klein et al., “Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors,”Exp. Neurol. 150:183-194, 1998.
Murphy et al., “Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin,”Proc. Natl. Acad. Sci. USA94:13921-13926, 1997.
Muzyczka, “Use of adeno-associated virus as a general transduction vector for mammalian cells,”Curr. Topics Microbiol. Immunol. 158:97-129, 1992.
Rosenfeld et al., “In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium,”Cell, 68:143-155, 1992.
Song et al., “Sustained secretion of human alpha 1-antitrypsin from murine muscle transduced with adeno-associated virus vectors,”Proc. Natl, Acad. Sci. USA, 95:14384-14388, 1998.
Guo et al., “Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer,”Gene Ther. 3:802-810, 1996.
Hofmann et al., “Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette,”Proc. Natl, Acad. Sci. USA93:5185-5190, 1996.
Hug et al., “Transcriptional repression by methylation: cooperativity between a CpG cluster in the promoter and remote CpG-rich regions,”FEBS Lett. 379:251-254, 1996.
International Search Report for Application No. PCT/US99/08921, dated Dec. 12, 1999.
Xiao et al., “Adeno-associated virus as a vector for liver-directed gene therapy,”J. Virol. 72:10222-10226, 1998.

Affiliated with

Also associated with

Rating

Materials and methods for gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Materials and methods for gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2948000